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Abstract Detailed molecular dynamics (MD) simu-
lations have been performed to reproduce and ratio-
nalize the experimental finding that the F483A
mutant of CYP2D6 has lower affinity for R-propran-
olol than for S-propranolol. Wild-type (WT) CYP2D6
does not show this stereospecificity. Four different
approaches to calculate the free energy differences
have been investigated and were compared to the
experimental binding data. From the differences be-
tween calculations based on forward and backward
processes and the closure of thermodynamic cycles,
it was clear that not all simulations converged suffi-
ciently. The approach that calculates the free energies
of exchanging R-propranolol with S-propranolol in
the F483A mutant relative to the exchange free
energy in WT CYP2D6 accurately reproduced the
experimental binding data. Careful inspection of the
end-points of the MD simulations involved in this
approach, allowed for a molecular interpretation of
the observed differences.
Introduction
The superfamily of cytochrome P450 (CYP) enzymes
constitutes the most important phase I metabolic en-
zymes. CYPs generally detoxify pharmacologically
active and potentially hazardous compounds, but in a
number of cases non-toxic parent compounds are bio-
activated into pharmacologically or toxicologically ac-
tive metabolites, or procarcinogens into their ultimate
carcinogens (Sheweita 2000; Vermeulen 1996). Al-
though the expression levels of CYP2D6 represent
only 2% of all hepatic CYPs, it is the second most
important drug metabolizing enzyme, after CYP3A4,
and involved in the metabolism of about 15–30% of the
currently marketed drugs (Bertilsson et al. 2002; Zan-
ger et al. 2004). Large interindividual differences exist
in CYP2D6 activity, due to gene multiplicity and
polymorphisms further emphasizing its clinical impor-
tance (Ingelman-Sundberg 2004; Oscarson and Ingel-
man-Sundberg 2002; Wormhoudt et al. 1999). The
early identification of potential CYP2D6 substrates
and prediction of their metabolism is therefore
advantageous in the discovery and development of new
drugs.
Experimentally, the active site of CYP2D6 can be
probed by site directed mutagenesis studies as de-
scribed in e.g. Flanagan et al. (2004), Keizers et al.
(2004, 2005b), Lussenburg et al. (2005) and Paine et al.
(2003). Such experiments can be designed from struc-
tural models of enzyme–substrate complexes and the
observed effect of mutations on metabolism and inhi-
bition can subsequently be rationalized at an atomic
resolution by modeling approaches. One mutant of
CYP2D6 that was proposed based on computational
models, is the F483A mutant (Lussenburg et al. 2005).
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The effect of this mutation on substrate binding affin-
ities and orientations was shown to be strongly
dependent on the substrate. For example, the metab-
olism of MAMC was no longer observed in the F483A
mutant and metabolism of bufuralol was reduced. On
the other hand no effects on the MDMA metabolism
were found, while for dextrometorphan several alter-
native metabolites were observed. The binding affinity
of these compounds did not seem to be influenced
significantly by the mutation. For the substrate
R-propranolol, however, the affinity is reduced by a
factor 20 upon mutation. Interestingly, a large stereo-
specific affinity is observed in the mutant CYP2D6, but
not in wild-type (WT). The metabolites formed from
both R- and S-propranolol remain the same upon
mutation of the enzyme (unpublished data).
In this study, we explore the stereospecific binding
of propranolol to wild-type CYP2D6 and the F483A
mutant. The spectral dissociation constants obtained
were computationally rationalized. Computational
tools may offer an atomic resolution often lacking in
experiments. In the present case, one expects that
subtle differences in the protein–ligand interactions in
WT CYP2D6 or in the F483A mutant have a deter-
mining influence on the observed affinities. In order to
catch such subtle differences a static approach based
on protein–ligand structures only will not likely suffice,
but rather the structure and dynamics of protein–ligand
interactions have to be taken into account, for instance
by molecular dynamics (MD) simulation. In CYPs it
was shown that docking and scoring strategies can be
applied to accurately predict binding modes and to
select high affinity compounds from chemical data-
bases (e.g. CYP101, CYP2D6 and CYP3A4) (de Graaf
et al. 2006; DeVoss and Demontellano 1995; DeVoss
et al. 1997; Kemp et al. 2004; Keseru 2001; Zhang et al.
1998). However, the scoring functions available in
docking programs show little or no correlation with
(experimental) binding affinity for these CYPs (Kemp
et al. 2004; Keseru 2001). In the case of MDMA
binding to CYP2D6 (WT and F120A mutant) it was
shown that a dynamic view on the interaction was
required to rationalize experimental findings (Keizers
et al. 2005a). Detailed MD simulations also offer the
possibility to calculate the free energy difference
between complexes of different proteins and ligands.
Previously, successful free energy calculations have
been reported using different methods. The linear
interaction energy (LIE) method (Aqvist et al. 1994)
was used for CYP101 (Paulsen and Ornstein 1996),
CYP1A1 (Szklarz and Paulsen 2002); free energy
perturbation (FEP) calculations (Beveridge and DiC-
apua 1989; Zwanzig 1954) for CYP101 (Helms and
Wade 1995; Jones et al. 1993) and a combination of
MD simulations, entropy estimates and Poisson–
Boltzmann calculations (MMPB-SA) (Kollman et al.
2000) for CYP2B4 (Harris et al. 2004).
A remaining hurdle in the accurate calculation of
CYP ligand binding affinity, however, is the diversity of
binding modes of substrates, stemming from a flexible
binding cavity that is large in relation to the size of the
substrates. Subsequently, for many substrates
the binding mode in CYPs is not as strictly defined as is
the case for many other more substrate specific
enzymes. This introduces sampling problems, prohib-
iting the application of MD based methods that can
provide the most accurate free-energy calculations.
In the case of R- and S-propranolol binding to WT
CYP2D6 and the F483A mutant, several approaches
can be made, making use of different thermodynamic
cycles (Tembe and McCammon 1984). We distinguish
four of such approaches, which are exemplified in
Fig. 1.
1. Calculate the free energy of inversion of R-pro-
pranolol into S-propranolol in solution and
when bound to protein (WT or F483): DGfreeinv ; DG
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Fig. 1 Four different approaches to calculate the differences in
binding affinities of R-propranol (R) and S-propranolol (S) to
wild-type (WT) and F483A mutant (F483A) CYP2D6, making
use of different thermodynamic cycles (described in the text).
Simulations at the initial and final stages along the solid arrows
are labeled with a small letter (also referred to in the text and in
Table 2)
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binding affinities of R- and S-propranolol in protein
(WT or F483A) can be obtained ðDDGWTbindðR; SÞ
and DDGF483Abind ðR; SÞÞ:
2. Calculate the free energy of inversion of R-pro-
pranolol into S-propranolol when bound to WT
and when bound to the F483A mutant: DGWTinv and
DGF483Ainv : From this the relative free energy of
transfer from WT to F483A for R- and S-pro-
pranolol can be obtained ðDDGtransferðR; SÞÞ:
3. Calculate the free energy of mutating the phenyl-
alanine sidechain into an alanine at position 483 in a
substrate free protein model and a substrate (R- or
S-propranolol) bound protein model DDGunboundmut ;
DGRmut and DG
S
mut: From this the relative binding
affinities of the ligand (R- or S-propranolol) to WT
and F483A can be obtained (DDGRbindðWT; F483AÞ
and DDGSbindðWT; F483AÞÞ:
4. Calculate the free energy of mutating the phenyl-
alanine side chain into an alanine at position 483
in a R-propranolol bound protein model and in a
S-propranolol bound protein model: DGRmut and
DGSmut: From this the relative free energy of
exchanging R-propranolol by S-propranolol in
WT and the F483A mutant can be obtained
(DDGexchange (WT,F483A)).
Each of these approaches yields information that can
be compared directly to the experimentally determined
differences in binding affinities of R- and S-propranolol
to WT and F483A CYP2D6. DGfreeinv ; representing the
inversion of the stereocenter of propranolol free in
solution, should equal zero. Because free energy is a
state function, combinations of individual free energy
terms defined above can be found that should sum up to
exactly zero ðDGcycleÞ: Comparisons of calculated to
experimental values and to theoretically defined values
will be used to determine which of the approaches is
most accurate and can be used to rationalize the ste-
reospecificity of the F483A mutant.
Methods
Optical titrations
Dissociation constants of the substrates to the enzymes
were determined by spectral titration, according to the
method of Jefcoate (1978). Spectra were taken at room
temperature on a Pharmacia Ultrospec 2000 spectro-
meter. In short, 1 ml of 0.5 lM purified enzyme in a
50 mM potassium phosphate buffer, pH 7.4 containing
10% glycerol, was divided over two cuvettes, to the first
5 ll of a 1 mM solution of R- or S-propranolol in the
same buffer was added, to the second the same volume of
just buffer. Difference spectra from 350 to 450 nm were
taken before, and after each addition of compound. The
substrates themselves did not show absorbance in this
spectral range at the concentrations used. The difference
between the absorbance at 390 and 425 nm was plotted
against the substrate concentration to estimate the dis-
sociation constant (Ks) using the following equation:
B ¼ Bmax½S
Ks þ ½S ð1Þ
where B is the absorbance difference (390–425) and
Bmax is the absorbance difference when [S] ﬁ ¥.
CYP2D6-propranolol model
Coordinates for a ligand bound model of cytochrome
P450 were obtained from homology modeling as de-
scribed in (de Graaf et al. 2007; Keizers et al. 2005a).
Very recently a model based on the crystal structure of
this isoenzyme has been published, but this involves a
ligand-free conformation of the protein (Rowland
et al. 2005). Our homology model was found to agree
with most of the details of the recently solved sub-
strate-free CYP2D6 crystal structure. Structural dif-
ferences between the homology model and crystal
structure were the same differences observed between
substrate-free and substrate-bound structures of other
CYPs (e.g. 2C5; Wester et al. 2003a, 2003b; Williams
et al. 2000), suggesting that these conformational
changes are required upon substrate binding (de Graaf
et al. 2007). For this reason we chose to rather use the
ligand-bound homology model, which was validated in
earlier MD simulations (Keizers et al. 2005a). Initial
coordinates for R-propranolol in complex with the
protein model were obtained by an automated docking
approach as described in (de Graaf et al. 2005a, 2006).
Molecular dynamics simulations
Molecular dynamics simulations and free energy calcu-
lations were performed along all solid angles in the
thermodynamic cycles in Fig. 1. All molecular dynamics
simulations were performed using a preliminary version
of the GROMOS05 programme (Christen et al. 2005).
Interaction parameters were taken from the GROMOS
43A1 force field (Van Gunsteren et al. 1996). For pro-
pranolol, parameters were determined according to
analogy to protein functional groups (see supplementary
material). The GROMOS force field is a united atom
force field, treating aliphatic hydrogen atoms together
with the carbon atoms to which they are bound as a
single interaction site. The wild-type protein was
Eur Biophys J (2007) 36:589–599 591
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solvated in a rectangular periodic box containing 5,314
(ligand free simulation) or 5,306 (with R-propranolol
bound) SPC water molecules (Berendsen et al. 1981).
For the simulations of propranolol free in solution, the
simulation box contained 2,367 water molecules. After
an initial energy minimization in which the protein was
positionally restrained, simulations were started at a
temperature of 300 K, maintaining harmonic restraints
with force constant 2,500 kJ mol–1 nm–2 on all solute
atoms.
The system was carefully heated up and equilibrated
as described in (Keizers et al. 2005a). Bond lengths were
constrained at their minimum energy values using the
SHAKE algorithm (Ryckaert et al. 1977) allowing for a
time step of 2 fs. Nonbonded interactions were calcu-
lated using a triple range cutoff scheme. Interactions
within a short range cutoff of 0.8 nm were calculated at
every time step from a pairlist that was generated every
five steps. Longer range interactions within a cutoff of
1.4 nm were calculated at pairlist generation and kept
constant between updates. To account for electrostatic
interactions beyond the long range cutoff, a reaction
field contribution to the energies and the forces was
calculated (Tironi et al. 1995). The temperature was
kept constant by coupling solute and solvent degrees of
freedom separately to a temperature bath of 300 K and
using a relaxation time of 0.1 ps (Berendsen et al. 1984).
Constant pressure was maintained by isotropically
coupling to a weak pressure bath of 1 atm using a
relaxation time of 0.5 ps and an estimated isothermal
compressibility of 4.575 · 10–4 (kJ mol–1 nm–3)–1.
Free energy calculations
Free energies were calculated along the solid arrows in
Fig. 1, using the thermodynamic integration method
(Beveridge and DiCapua 1989; Kirkwood 1935). The
arrows in this figure connect an initial (A) and a final
(B) state, which can be defined as: (1) R-propranolol
(A) versus S-propranolol (B) free in solution; (2) R-
propranolol (A) versus S-propranolol (B) bound to
wild-type and F483A mutant CYP2D6, respectively;
(3) unbound wild-type (A) versus unbound F483A
mutant (B) CYP2D6; (4) wild-type (A) versus F483A
mutant (B) binding R- and S-propranolol, respectively.
The Hamiltonians describing the initial and final states
of each process were related using a coupling param-
eter k, such that at k = 0 the Hamiltonian described the
initial state and at k = 1, it described the final state of
the process. Simulations were performed at a number
of discreet k-values and the free energy was obtained
by numerical integration of the derivative of the
Hamiltonian with respect to k:
DGBA ¼
Z1
0
@Hðr; p; kÞ
@k
 
k
dk ð2Þ
where Æ¶H(r, p, k)/¶kæk represents an ensemble average
obtained at the specified value of k, r and p are the
positions and momenta of all particles in the system.
Free energies of mutating residue 483 and of R/S
inversion of propranolol were calculated as shown
Fig. 2. Processes involving the inversion of the chiral
center of propranolol were performed in a two-step
process (Zhou et al. 2005, 2006). First one stereoisomer
was transformed into a planar intermediate (I), using
six simulations for the integration of Eq. 2. The
intermediate state was subsequently transformed into
the alternative stereoisomer, using again six equidistant
values of k. Processes involving the transformation
of residue 483 were obtained from 11 simulations
at equidistant k-values. Aromatic atoms in F483 were
changed into non-interacting dummy atoms, while Cb
R ”I“ S
384A384F
ud
ud
ud
ud
ud
ud
ud
ud
ud
ud
udO
N
H
H
H
H
H
HO
N
H
H
H
H
O H
H
H
O
H
H
N
H H
lolonarporp
6D2PYC
H
H
H
O H
H
H
O
H
H
N
H H H
H
H
O H
H
H
O
H
H
N
H H
***
Fig. 2 Schemes describing
the (reversible) inversion of
R- into S-propranolol and the
(reversible) mutation of the
residue on position 483 in
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was changed from a CH2 group into a CH3 group. The
nonbonded interactions at intermediate k-values were
described using the soft-core approach to avoid
singularities in the derivative (Beutler et al. 1994). No
changes were made in the covalent interactions. Twenty
ps of equilibration were followed by 200 ps of data
collection at every k-value. Statistical error estimates on
the ensemble averages were obtained using block
averages (Allen and Tildesley 1987). Simulations with
relatively large statistical errors were prolonged for
another 200 ps, and additional points were added
wherever needed to obtain a smooth profile of Æ¶H/¶kæ
as a function of k. A more empirical error estimate was
obtained by comparing calculated free energy values
associated with a forward process and the corresponding
reverse process, also called hysteresis. An average free
energy estimate from the forward and backward
processes can be calculated using Boltzmann weighted
averages using (Jarzinsky 1997; Lu et al. 2003):
DGaverage ¼kBT ln 1
2
eDGforward=kBT þeDGbackward=kBT
h i 
ð3Þ
A total of 76 simulations (6 · 2 · 6 + 4 added k-
points) were performed involving R/S inversions and
72 simulations (6 · 11 + 6 added k-points) were per-
formed involving F/A mutations. This leads to an
overall simulation time of 33 ns.
Results
Experimental results
Both the propranolol enantiomers displayed a type I
binding spectrum when added to wild-type CYP2D6,
as derived from a decrease of the Soret maximum at
417 nm, and the appearance of a shoulder at 380 nm,
which is typical for type I binding of a substrate (Jef-
coate 1978). The affinity of the wild-type enzyme for
the R- and S-enantiomers was similar (Table 1).
The addition of S-propranolol to the F483A mutant
gave the same results as obtained for wild-type
CYP2D6. The addition of R-propranolol to the F483A
mutant of CYP2D6 did also lead to a type I spectrum,
however, the affinity was 20-fold lower compared to
the wild-type enzyme.
Computational approaches
Simulations at the initial and final stages along the solid
arrows in Fig. 1 have been analyzed in detail. For every
combination of R- or S-propranolol and WT or F483A
mutant, four of such simulations of 200 ps were
performed, labeled with small letters in Fig. 1. The four
simulations included the end points of at least two
different processes (R/S-inversion or F/A mutation)
allowing for a comparison of convergence at every state.
The atom-positional root-mean-square deviation of
Ca atoms with respect to the initial homology model,
remained stable throughout the simulations, with
maximum values of 0.25 nm. For a 464 residue protein
(the N-terminus of the homology model is truncated by
33 residues) such values are reasonable and indicate
simulations of a stable protein structure.
Binding mode orientation
The active site of CYP2D6 is formed by substrate
recognition sites (SRS) 1 (B–C loop), 2 (F-helix), 4
(I-helix), 5 (b1-4) and 6 (b4-1). Figure 3 displays a top
view of the active site with interacting residues dis-
played in stick. The protonated nitrogen atom and the
hydroxyl group of propranolol can form a hydrogen
bond network with the negatively charged carboxylate
of E216 (not visible in Fig. 3, but shown in Fig. 5). Two
binding modes for the naphthalene moiety can be dis-
tinguished (see Fig. 3). In WT CYP2D6, propranolol
occupies a hydrophobic cavity formed by F120, V308,
V370, and F483 (binding mode 1). In the F483A mu-
tant, a larger cavity becomes available and SRS5
slightly shifts. The naphthalene moiety of propranolol
now occupies a cavity formed by F120, V374, V370 and
A483 (binding mode 2). In order to distinguish these
binding modes, an atomic distance and an angle are
defined in Fig. 3. The distance between the heme NB
atom and the C5 atom of propranolol will be larger in
binding mode 2. The angle defined by the Cn atom in
F120, the C5 atom of propranolol and the Cb in V370
will approach 180 in binding mode 2. All simulations
originated from the WT protein and R-propranolol
occupying binding mode 1. During the free energy
calculations, the ligand was seen to move to binding
mode 2. Table 2 presents the average values of the NB-
C5 distance and the Cn–C5–Cb angle over the end-point
Table 1 Ks values (lM) of S- and R-propranolol for wild-type
and F483A mutant CYP2D6
Ligand Ks (lM)
Wild-type F483A
S-propranolol 26 ± 6 23 ± 2
R-propranolol 19 ± 3 376 ± 26
All values are the means of at least two independent experi-
ments; ±SD as described in the experimental procedures
Eur Biophys J (2007) 36:589–599 593
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simulations, together with the average number of
hydrogen bonds between propranolol and E216. The
presence of a hydrogen bond was determined using
geometric criteria: a donor–acceptor distance of at most
0.25 nm and a H-bond angle of at least 135. Alterna-
tive hydrogen bonds partners of propranolol were not
observed for significant periods of time.
Free energy calculations
The values of Æ¶H/¶kæ as a function of k are displayed in
Fig. 4 for all thermodynamic integration simulations.
Values for the backward processes are multiplied by
–1, for ease of comparison to the forward processes.
Free energy estimates for all processes were obtained
by a simple trapezoid integration of these curves and
the resulting free energies are presented in Table 3.
Using the definitions in Fig. 1, the different relative
free energies are calculated and compared to experi-
mental values.
Discussion
The primary aim of this study was to reproduce and
rationalize the experimental finding that the F483A
mutant of CYP2D6 has lower affinity for R-propranolol
than for S-propranolol, using detailed molecular
dynamics (MD) simulations. From these simulations,
free energy estimates for all processes in Fig. 1 have
Fig. 3 Representative snapshots of two distinct binding modes
observed in simulations of WT CYP2D6 (binding mode 1, left
panel) and the F483A mutant (binding mode 2, right panel).
Propranolol is depicted in yellow sticks and hydrophobic
substrate binding amino acid residues are depicted in grey ball-
and- sticks. Two geometric features used to discriminate between
the two binding modes are displayed: the distance between the
nitrogen atom of heme pyrrole ring B (NB) and the C5 atom of
R-propranolol and the angle defined by the Cn atom in F120, the
C5 atom in R-propranolol and the Cb in V370
Fig. 4 The values of Æ¶H/¶kæ
as a function of k for the
calculation of the following
free energy values. Panel 1
DGfreeinv forward (solid) and
backward (dotted). Panel 2
DGWTinv forward (solid) and
backward (dotted), DGF483Ainv
forward (dashed) and
backward (dash-dot). Panel 3
DGunboundmut forward (solid) and
backward (dotted). Panel 4
DGRmut forward (solid) and
backward (dotted); DGSmut
forward (dashed) and
backward (dash-dot)
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been derived, which are presented in Table 3. The error
estimates in Table 3 should be considered as statistical
error estimates, indicating the statistical precision of the
calculation. The absolute accuracy, however, is more
difficult to determine. Three criteria that may give an
indication of the accuracy can be distinguished. First, the
hysteresis, defined as the difference between performing
a process in the forward and backward directions, yields
information on the convergence of the directions. At
infinite sampling times, the hysteresis will be equal to
zero. In Table 3, two cases can be observed with rela-
tively large hystereses, the R/S inversion of propranolol
in WT CYP2D6 and the F/A mutation in S-propranolol
bound protein. In the other cases the hysteresis falls
within the statistical uncertainty. Second, using the
studied processes, one can obtain cyclic pathways along
Table 2 Average values and
standard deviations of the
geometric features defined in
Fig. 3 together with the
average number of hydrogen
bonds between propranolol
and E216 for the different
MD-simulations at the initial
and final stages of the
inversion and mutation
processes defined in Fig. 1
The results belonging to
approach 2 (defined in Fig. 1)
are displayed in bold
Simulations Propranolol CYP2D6 Average
H-bonds
NB-C5
distance (A˚)
F120 Cn–C5–V370Cb
angle (deg)
e R-propranolol WT 2.2 4.7 ± 0.3 90 ± 6
f 2.2 5.4 ± 0.4 111 ± 9
g S-propranolol WT 2.4 4.7 ± 0.3 92 ± 5
h 2.6 4.5 ± 0.3 87 ± 4
i R-propranolol F483A 2.1 8.3 ± 0.5 159 ± 10
j 2.4 8.0 ± 1.9 138 ± 27
k S-propranolol F483A 2.7 10.5 ± 0.7 117 ± 12
l 2.1 8.6 ± 1.8 134 ± 23
q R-propranolol WT 2.4 6.6 ± 0.5 157 ± 13
r 2.2 4.8 ± 0.3 103 ± 6
s S-propranolol WT 1.5 4.6 ± 0.3 88 ± 5
t 2.2 4.8 ± 0.3 83 ± 4
u R-propranolol F483A 2.5 4.9 ± 0.6 104 ± 11
v 2.5 5.2 ± 0.7 101 ± 21
w S-propranolol F483A 1.7 5.0 ± 0.5 90 ± 6
x 1.7 4.9 ± 0.4 89 ± 5
Fig. 5 Representative
orientations of R- and S-
propranolol in the binding
cavities of WT and mutant
CYP2D6 observed during the
MD-simulations at points
defined in Fig. 1 and included
in approach 2: e (WT: R),
g (WT: S), i (F483A: R), and
k (F483A: S). R-propranolol
forms fewer hydrogen bonds
than S-propranolol in the
F483A mutant. The F483A
mutation also causes a loss of
favourable hydrophobic
interactions, which can be
compensated by increased
hydrogen bond formation by
S-propranolol, but not by
R-propranolol
Eur Biophys J (2007) 36:589–599 595
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which the sum of free energies should be equal to zero.
In Table 3, such a pathway is presented as DGcycle: It is
clear that the present calculations do not meet this cri-
terion, with values of DGcycle larger than the statistical
uncertainty. This indicates that not all free energy cal-
culations have converged properly. The third criterion is
the ability to reproduce experimental data. Knowing
that not all simulations have reached convergence, this
last criterion allows us to determine if any of the four
approaches mentioned in the introduction can still be
used to rationalize the experimental data at an atomic
level.
Free energies of binding: approaches 1 and 3
In the first approach, the relative free energies of
binding R- and S-propranolol are determined for both
proteins. This approach uses a simulation of the R/S-
inversion free in solution, of which the free energy
value should fundamentally equal zero. As can be seen
in Table 3, indeed DGfreeinv is calculated to be 0 within
the error estimate. However, the relative free energies
DDGWTbindðR; SÞ and DDGF483Abind ðR; SÞ do not correspond
to the experimentally determined value. The inversion
process of propranolol when bound to the protein
seems to be too unfavourable. Still, this may be due to
a systematic contribution in the protein simulations,
which would cancel in approach 2, where only free
energies resulting from simulations of the propranolol
inversion when bound to the protein are compared.
In the third approach, the relative free energies of
binding R- and S-propranolol to the WT and mutant
CYP2D6 protein are calculated and compared. The
mutation in the ligand-free protein shows the smallest
hysteresis in Table 3. The obtained value of
DDGRbindðWT; F483AÞ is within 4 kJ mol–1 of the
experimental value, which is within the statistical
uncertainty, but not satisfactory. The value of
DDGSbindðWT; F483AÞ is even further from the experi-
mental value. Note that the value of DGSmut shows the
largest hysteresis, indicating that particularly these
simulations may not have converged properly. An indi-
cation of the convergence can be obtained by comparing
simulations k and l to simulations w and x in Fig. 1 in
terms of the structural properties. From the average
distance and angle in Table 2, we can see that in simu-
lations k and l, the naphthalene moiety of S-propranolol
binds in binding mode 2, while in simulations w and x, S-
propranolol still orients according to binding mode 1
(see Fig. 2). This difference indicates that the processes
(R/S inversion in the mutant protein, or F/A mutation
with S-propranolol bound) do not converge to the same
Table 3 Free energy
estimates, the resulting
average free energies, and the
relative free energies for all
processes defined in Fig. 1
and compared to
experimentally determined
values
a Average determined
according to Eq. 3
b Hysteresis, defined as the
difference between
performing a process in the
forward and backward
directions, yields information
on the convergence of the two
independent calculations
Forward Backward Averagea Hysteresisb
DGfreeinv –0.4 ± 1.5 –1.0 ± 1.8 –0.7 0.6
DGWTinv 10.6 ± 1.5 19.1 ± 1.7 12.2 8.5
DGF483Ainv 3.6 ± 2.1 6.8 ± 1.9 4.7 3.2
DGunboundmut 35.8 ± 3.0 36.0 ± 3.5 35.9 0.2
DGRmut 36.8 ± 2.0 40.2 ± 2.7 38.0 3.4
DGSmut 50.5 ± 4.3 41.3 ± 2.5 42.9 9.2
DGcycle 20.7 ± 11.4 13.4 ± 8.8 12.5
Averagea Experimental
Approach 1
DDGWTbindðR; SÞ 12.9 0.8
DDGF483Abind ðR; SÞ 5.4 –6.9
Approach 2
DDGtransferðR; SÞ –7.5 –7.7
Approach 3
DDGRbindðWT; F483AÞ 2.1 7.4
DDGSbindðWT; F483AÞ 7.0 0.3
Approach 4
DDGexchange (WT,F483A) 5.0 –7.1
596 Eur Biophys J (2007) 36:589–599
123
end point. This is also reflected by significant differences
in H-bond counts (see Table 3): S-propranolol forms
more H-bonds with E216 in the F483A mutant in sim-
ulations k and l than it does in simulations w and x. A
similar difference in the average number of hydrogen
bonds between S-propranolol and E216 in WT is ob-
served when comparing simulations g and h with simu-
lations s and t. This indicates that S-propranolol occupies
a different area in phase space during the F/A mutation
than during the other simulations leading to the same
end-points. With these observations, we also find an
explanation for the non-zero value of DGcycle: Since not
all end-points of the simulations are connected, the
calculated cycle is not complete.
Free energies of transfer and exchange: approaches
2 and 4
Approach 4 uses the same mutational processes with
propranolol bound to the protein as were used in ap-
proach 3. From these values the free energies of
exchanging R-propranolol by S-propranolol in the
mutant relative to WT (DDGexchange (WT,F483A)) can
be obtained. As was discussed above, the F/A mutation
with S-propranolol bound does not converge to the
same end-points. For this reason it should not be ex-
pected that the value of DDGexchange (WT,F483A) will
correspond to the experimental data (Table 3).
The only approach for which the calculated free
energies match the experimental data appears to
be approach 2. In this approach, the free energy of
transferring R-propranolol from WT CYP2D6 to the
F483 mutant is calculated relative to the free energy of
transferring S-propranolol ðDDGtransferðR; SÞÞ: The ob-
tained value lies only 0.2 kJ mol–1 from the experi-
mental value, which is well within the statistical error
estimate of the calculations. It is also within kBT
(~2.5 kJ mol–1), corresponding to thermal fluctuations,
which is the accuracy that can be expected from free
energy calculations (Brandsdal et al. 2003; van Gunst-
eren et al. 2002).
In summary, the approaches using protein mutations
(i.e., 3 and 4) do not converge sufficiently to reproduce
the experimental data. A systematic error in the R/S
inversion for protein-bound propranolol disqualifies
approach 1, but still allows for a comparison with ap-
proach 2 (the inversion in the different proteins), which
does yield free energy values in agreement with the
experimental data. From Fig. 4 it can be seen that Æ¶H/
¶kæ takes much larger values in the processes involving
a mutation than in the processes involving an inversion.
It has been shown earlier that free energy calculations
involving smaller structural changes and smaller
energy barriers yield more accurate free energy esti-
mates than integrations involving large changes in Æ¶H/
¶kæ (Mark et al. 1991; Zhou et al. 2005).
Possibly, better results with lower hysteresis and
cycle closure, could be obtained by further extending
the length of the simulations and by adding more
k-points (Mark et al. 1991; Oostenbrink and Van
Gunsteren 2006). Another possible source of error
could be the fact that a (substrate-bound) homology
model was used, which has slightly different properties
than the recently solved substrate-free crystal struc-
ture. However, we conclude that the changes required
in the active site of CYP2D6 upon ligand binding are
so large (de Graaf et al. 2007; Rowland et al. 2005)
that the use of the homology model is justified. In
addition, CYP2D6 will remain a challenging target for
computational approaches, because of the broad range
of inhibitors and substrates and the multiple binding
modes observed for these (de Graaf et al. 2005b).
Now that we have determined that approach 2
reproduces the experimental data best, it is of interest
to investigate the molecular basis for the calculated
free energies in this approach.
Structural rationalization
In order to rationalize the difference in affinity for R-
and S-propranolol upon mutation of residue 483, we
can compare the observed binding modes in simula-
tions e – l in Fig. 1. Representative orientations of
propranolol in the binding cavities of WT and mutant
protein in these simulations are presented in Fig. 5. In
all simulations propranolol is involved in a salt bridge
between the protonated nitrogen atom and the nega-
tively charged E216 in the protein. Together with the
propranolol hydroxyl group, these three moieties form
a dynamic hydrogen bond network. The average
number of hydrogen bonds observed throughout the
simulations, however varies for different combinations
of R/S-propranolol and WT/F483A proteins. Already
in WT (simulations e – h), we observed fewer hydro-
gen bonds for R-propranolol than for S-propranolol
(see Table 2 and Fig. 5).
For both stereoisomers, the naphthalene moiety
orients itself according to binding mode 1, it fits snugly
into a hydrophobic pocket formed by V308, V370, and
F483 (pocket 1, see Figs. 3, 5). Upon the F483A
mutation, the size of the pocket increases, which op-
poses tight hydrophobic interactions. The naphthalene
moiety now occupies the pocket formed by F120, V370,
V374 and A483 (pocket 2), according to binding mode
2, as indicated by a larger value of the heme-NB to
propranolol-C5 distance (see Table 2). A large value of
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the Cn–C5–Cb angle indicates that a position between
F120 and V370 is occupied. In the F483A mutant,
R-propranolol binds in pocket 2 without significant
decrease in the average number of hydrogen bonds
(simulations i and j), compared to the simulations
performed in WT (e and f). When S-propranolol binds
in pocket 2 in F483A, hydrogen bond interactions are
lost, in particular the propranolol-OH to E216-Oe
hydrogen bond is observed only for 50% of the time in
simulation l. This hydrogen bond can be regained by
moving away from F120 and V370 (angle Cn–C5–Cb
decreases) in simulation k. In fact the average number
of hydrogen bonds in this simulation is even larger than
for S-propranolol in WT, compensating the lack of
tight hydrophobic interactions at the naphthalene
moiety. R-propranolol cannot compensate for this loss.
In summary, the following picture arises. R-pro-
pranolol forms fewer hydrogen bonds than S-propra-
nolol, both in WT and in the F483A mutant. The
mutation causes a loss of favourable hydrophobic
interactions, which can be compensated by increased
hydrogen bond formation by S-propranolol, but not by
R-propranolol.
Conclusions
Detailed molecular dynamics (MD) simulations have
been performed to reproduce and rationalize the
experimental finding that the F483A mutant of
CYP2D6 has lower affinity for R-propranolol than for
S-propranolol. Wild-type (WT) CYP2D6 does not
show this stereospecificity. Four different approaches
to calculate the free energy differences have been
investigated and were compared to the experimental
binding data. From the differences between calcula-
tions based on forward and backward processes and
the closure of the thermodynamic cycles, it was clear
that not all simulations have converged sufficiently.
The approach that calculates the free energies of
exchanging R-propranolol with S-propranolol in the
F483A mutant relative to the exchange free energy in
WT accurately reproduced the experimental binding
data. Careful inspection of the end-points of the sim-
ulations involved in this approach, allowed for a
molecular interpretation of the observed differences.
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